Ying Hu | Cancer Biology and Cancer Treatment | Best Researcher Award

Posted on by ScienceFather

Prof Ying Hu | Cancer Biology and Cancer Treatment | Best Researcher Award

Professor, Harbin Institute of technology, China

Prof. Ying Hu is a distinguished cancer biologist renowned for her groundbreaking research in tumor gene function, drug resistance, and cancer metastasis. With a PhD in Cancer Biology from University College London and an MPhil in Clinical Oncology from The Chinese University of Hong Kong, she has established herself as a leader in the field. Currently leading the tumor gene function study group at Harbin Institute of Technology, Prof. Hu focuses on uncovering novel therapeutic targets and mechanisms in cancer. Her work on oncogenes, long non-coding RNAs (lncRNAs), and the tumor microenvironment has been published in top-tier journals like Cancer Cell and PNAS. Prof. Hu is an active member of the Chinese Anti-Cancer Association and the Chinese Society for Cell Biology. Her research has significantly advanced our understanding of cancer biology, earning her recognition as a key contributor to the fight against cancer.

Professional Profile

Orcid

Scopus

Education 🎓

Prof. Ying Hu holds a PhD in Cancer Biology from University College London (2004-2009), where she specialized in tumor gene function. She earned her MPhil in Clinical Oncology from The Chinese University of Hong Kong (2002-2004) and an MS in Biochemistry and Molecular Biology from Fudan University (1999-2002). Her foundational education includes an MB in Chemical Analysis from Shandong Medical University (1994-1999). This diverse academic background has equipped her with a multidisciplinary approach to cancer research, combining molecular biology, clinical oncology, and biochemistry. Her education has been instrumental in shaping her innovative research strategies, enabling her to explore complex mechanisms of cancer progression and drug resistance.

Experience 💼

Prof. Ying Hu has over a decade of experience in cancer research. She currently leads the tumor gene function study group at Harbin Institute of Technology (2012-present), focusing on drug resistance and metastasis. Prior to this, she worked as a researcher at the University of Oxford (2009-2012), where she contributed to oncology research. Her expertise spans cellular and molecular biology, animal tumor models, and human sample analysis. Prof. Hu’s leadership has driven significant discoveries in cancer biology, including the role of lncRNAs and oncogenes in tumor progression. She is also an active member of professional organizations, including the Chinese Anti-Cancer Association and the Chinese Society for Cell Biology. Her extensive experience and leadership in cancer research have established her as a prominent figure in the field.

Awards and Honors 🏆

Prof. Ying Hu has received recognition for her outstanding contributions to cancer research. Her work has been featured in high-impact journals, with several papers highlighted as “Featured Articles” in Cancer Cell and PNAS. She has been an invited speaker at numerous international conferences, sharing her insights on cancer biology and drug resistance. Prof. Hu’s research on iASPP and lncRNAs has been widely cited, reflecting its significance in the field. She is a council member of the Chinese Society for Cell Biology (2019-present) and an active member of the Chinese Anti-Cancer Association. Her leadership and innovative research have earned her a reputation as a leading scientist in cancer biology. While specific awards are not listed, her consistent publication in top-tier journals and professional recognition underscore her achievements.

Research Focus 🔬

Prof. Ying Hu’s research focuses on understanding the mechanisms of drug resistance and cancer metastasis, the leading causes of cancer-related mortality. Her work explores the activation and function of oncogenes, such as the ASPP family proteins, and the roles of long non-coding RNAs (lncRNAs) in cancer progression. She investigates the interplay between tumor cells and the tumor microenvironment, using cellular and molecular strategies, animal models, and human samples. Key areas of her research include the regulation of apoptosis, ferroptosis, and DNA damage repair in cancer cells. Prof. Hu’s discoveries have identified novel therapeutic targets and provided insights into overcoming drug resistance. Her innovative approaches have advanced our understanding of cancer biology and opened new avenues for cancer treatment.

Publication Top Notes 📚

  1. iASPP is an antioxidative factor and drives cancer growth and drug resistance by competing with Nrf2 for Keap1 binding.
  2. SMURF2 predisposes cancer cells toward ferroptosis in GPX4-independent manners by promoting GSTP1 degradation.
  3. Long noncoding RNA HITT coordinates with RGS2 to inhibit PD-L1 translation in T cell immunity.
  4. ER-associated degradation ligase HRD1 links ER stress to DNA damage repair by modulating the activity of DNA-PKcs.
  5. iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca2+ homeostasis and control tumor growth and drug resistance.
  6. Calcium homeostasis and cancer: insights from endoplasmic reticulum-centered organelle communications.
  7. AKAP1/PKA-mediated GRP75 phosphorylation at mitochondria-associated ER membranes protects cancer cells against ferroptosis.
  8. iASPP suppression mediates terminal UPR and improves BRAF-inhibitor sensitivity of colon cancers.
  9. A novel LncRNA HITT forms a regulatory loop with HIF-1α to modulate angiogenesis and tumor growth.
  10. A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers.
  11. LncRNA HITT inhibits metastasis by attenuating Rab5-mediated endocytosis in lung adenocarcinoma.
  12. iASPP is essential for HIF-1α stabilization to promote angiogenesis and glycolysis via attenuating VHL-mediated protein degradation.
  13. A lncRNA coordinates with Ezh2 to inhibit HIF-1α transcription and suppress cancer cell adaption to hypoxia.
  14. A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells.
  15. Mitochondria-localized lncRNA HITT inhibits fusion by attenuating formation of mitofusin-2 homotypic or heterotypic complexes.
  16. lncRNA HITT Inhibits Lactate Production by Repressing PKM2 Oligomerization to Reduce Tumor Growth and Macrophage Polarization.
  17. HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth, and drug resistance in renal cell carcinoma.
  18. Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
  19. EGR-1/ASPP1 inter-regulatory loop promotes apoptosis by inhibiting cyto-protective autophagy.
  20. Upregulation of MiR-205 under hypoxia promotes epithelial-mesenchymal transition by targeting ASPP2.
  21. A p53/CPEB2 negative feedback loop regulates renal cancer cell proliferation and migration.
  22. Nuclear iASPP determines cell fate by selectively inhibiting either p53 or NF-κB.
  23. Identification of lncRNA-Protein Interactions by CLIP and RNA Pull-Down Assays.
  24. Cell autonomous role of iASPP deficiency in causing cardiocutaneous disorders.
  25. iASPP prevents premature cellular senescence and is required for normal epithelial stratification.
  26. iASPP: A Novel Desmosome Regulator and its Deficiency Causes Arrhythmogenic Right Ventricular Cardiomyopathy.
  27. Restoring p53 function in human melanoma cells by inhibiting mdm2 and cyclinB1/cdk1 phosphorylated nuclear iASPP.

Conclusion 🏅

Prof. Ying Hu is a highly accomplished cancer biologist whose research has significantly advanced our understanding of drug resistance, cancer metastasis, and tumor gene function. With a strong educational background, extensive research experience, and numerous high-impact publications, she has established herself as a leader in the field. Her innovative approaches and discoveries have identified novel therapeutic targets and provided insights into overcoming cancer progression. Prof. Hu’s contributions to cancer biology make her a deserving candidate for the Best Researcher Award. Her work continues to inspire and pave the way for future breakthroughs in cancer treatment.

Mohamed Hassan | Tumor prevention and Therapy | Best Paper Award

Posted on by ScienceFather

Assist. Prof. Dr Mohamed Hassan | Tumor prevention and Therapy | Best Paper Award

Senior researcher, Tulane university school of medicine, United States

Mohamed Hassan is a distinguished researcher specializing in molecular oncology and translational medicine. He earned his Ph.D. from the University Hospital of Düsseldorf, Germany, focusing on Hepatitis C virus interactions with intracellular signaling. With extensive postdoctoral training in gastroenterology, pathology, and molecular tumor therapy, he has held academic positions in leading institutions across Germany, France, and the USA. His research spans cancer progression, drug resistance, and the tumor microenvironment, contributing to high-impact publications. Recognized globally for his scientific excellence, he has received prestigious awards, including the Italian Ministry of Health Award and the Japanese Society of Internal Medicine Award.

PROFESSIONAL PROFILE

Orcid

EDUCATION

  • Ph.D. (2001), University Hospital of Düsseldorf, Germany – Research on Hepatitis C virus core protein interference in liver cells.
  • M.Sc. (1996), University of Düsseldorf, Germany – Study on cDNA expression in malaria-immune mice.
  • B.Sc. (1983), Zagazig University & University of Düsseldorf, Germany.
  • Further Training: Teaching certification (University of Mississippi Medical Center, 2015), Clinical Research Associate (Germany, 2011), eLearning applications (University of Köln, 2008), and animal experimentation training (University of Düsseldorf, 2005).

EXPERIENCE

  • Senior Postdoctoral Fellow & PI – Institut National de la Santé et de la Recherche Médicale, University of Strasbourg (2007-2013).
  • Research Assistant Professor – Tulane University, USA (2016-2018); University of Strasbourg, France (2018-present).
  • Instructor – University of Mississippi Medical Center (2013-2016).
  • Postdoctoral Fellow – University Hospital of Düsseldorf (2001-2004).
  • Research Assistant – University Hospital of Düsseldorf (1996-2001); University of Düsseldorf (1992-1996).

AWARDS AND HONORS

🏅 2016 – Italian Ministry of Health Award for Research & Innovation.
🏅 2016 – Award of Excellence in Reviewing by Spandido Publications.
🏅 2011 – Japanese Society of Internal Medicine Outstanding Researcher Award.

RESEARCH FOCUS

🔬 Cancer Biology – Investigating tumor progression, metastasis, and resistance mechanisms.
🧬 Molecular Oncology – Targeting non-receptor tyrosine kinases in cancer therapy.
💊 Translational Medicine – Developing novel therapeutic strategies against cancer stem-like cells.
🦠 Immuno-oncology – Exploring immune checkpoint inhibitors and their effects.
🧑‍⚕️ Clinical Research – Bridging molecular insights with patient-centered treatments.

PUBLICATIONS

📄 Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events – International Journal of Molecular Sciences (2024)
📄 Non-Receptor Tyrosine Kinases in Tumor Progression and Resistance – Cancers (2024)
📄 hTERT Epigenetics & Chemotherapy Guidance – International Journal of Molecular Sciences (2024)
📄 CD133-Dependent Activation in Melanoma Progression – Cells (2024)
📄 Mechanisms of Melanoma Progression & Treatment Resistance – Cancers (2024)
📄 Tumor Microenvironment as a Therapeutic Target in Melanoma – Cancers (2023)
📄 Toll-like Receptors in Antimicrobial Protein Expression – International Journal of Molecular Sciences (2023)
📄 Antimicrobial Proteins: Structure & Therapeutic Potential – Pharmaceutics (2022)

CONCLUSION

Mohamed Hassan is a leading figure in molecular oncology, contributing groundbreaking research in cancer progression and therapy resistance. His work has been recognized internationally, and he continues to drive impactful discoveries in translational medicine and immuno-oncology. His commitment to scientific excellence is evident in his numerous high-impact publications and global collaborations. 🚀

John Tsiaoussis | Translational Oncology | Best Paper Award

Posted on by ScienceFather

Prof. John Tsiaoussis | Translational Oncology | Best Paper Award

John Tsiaoussis at School of Medicine, University of Crete, Greece

Dr. John C. Tsiaoussis is a distinguished Professor of Anatomy at the University of Crete’s School of Medicine, where he also serves as Head of the Department of Anatomy and Director of the Museum of Medicine. With a robust academic background, Dr. Tsiaoussis has delivered over 100 invited lectures at international and national conferences. His prolific research output includes more than 100 publications in peer-reviewed journals, garnering around 3,500 citations and an H-index of 33. His work emphasizes the importance of anatomical education and research in enhancing medical practice, particularly in understanding colorectal cancer. Dr. Tsiaoussis actively engages in editorial roles across multiple medical journals, furthering the discourse in surgical and functional anatomy. His commitment to advancing medical knowledge and education makes him a leading figure in his field.

Profile:

Scopus Profile

Strengths for the Award:

  1. Extensive Publication Record:
    • Over 100 publications in peer-reviewed journals and 6 book chapters, showcasing a strong commitment to research and knowledge dissemination.
  2. High Citation Impact:
    • 3,500 citations with an H-index of 33 indicate significant recognition and impact within the scientific community.
  3. Diverse Research Interests:
    • Focus on important areas like biomarkers in colorectal cancer and surgical anatomy, contributing to significant advancements in understanding and treatment.
  4. Leadership Roles:
    • As Head of Department and Director of the Museum of Medicine, demonstrates leadership in academia and commitment to education and research.
  5. Invited Lectures:
    • Over 100 invited lectures at national and international events, reflecting expertise and reputation in the field.
  6. Editorial Contributions:
    • Long-standing role as Editor and Guest Editor in respected journals, contributing to the peer review process and the advancement of medical research.

Areas for Improvement:

  1. Broader Research Collaboration:
    • While Dr. Tsiaoussis has a strong individual publication record, seeking out more interdisciplinary collaborations could enhance the breadth and impact of his research.
  2. Engagement with Emerging Technologies:
    • Exploring the integration of advanced technologies (e.g., AI, machine learning) in research could provide innovative approaches to his work in cancer biomarkers and surgical anatomy.
  3. Increased Public Outreach:
    • Enhancing efforts to translate research findings to the general public could improve awareness and understanding of colorectal cancer and surgical practices.

Education:

Dr. Tsiaoussis obtained his medical degree from the University of Crete, where he demonstrated exceptional academic performance and a keen interest in anatomy. He continued his education with a specialization in anatomy, gaining a comprehensive understanding of both surgical and functional aspects. His academic journey was marked by rigorous training and research, which laid the groundwork for his later contributions to the field. Dr. Tsiaoussis pursued further training and certifications that expanded his expertise in anatomical sciences, including advanced techniques in surgical anatomy. His educational background is complemented by numerous workshops and training sessions, allowing him to remain at the forefront of medical education. Dr. Tsiaoussis is committed to lifelong learning and regularly updates his skills to incorporate the latest advancements in medical science into his teaching and research methodologies.

Experience:

Dr. John C. Tsiaoussis has an extensive academic and clinical background that spans several decades. As the Head of the Department of Anatomy at the University of Crete, he has been instrumental in shaping the curriculum and research direction within the department. His role includes overseeing educational programs, mentoring students, and facilitating collaborative research efforts. He has held numerous editorial positions in esteemed medical journals, contributing to the peer-review process and enhancing the quality of published research. Dr. Tsiaoussis’s experience extends to delivering over 100 invited lectures globally, sharing his expertise in anatomical research and colorectal cancer biomarkers. His involvement in international symposiums and workshops underscores his dedication to advancing medical education and research. He is recognized for his leadership in fostering a dynamic academic environment that encourages innovation and excellence in the field of anatomy and surgery.

Research Focus:

Dr. Tsiaoussis’s research primarily centers on biomarkers in colorectal cancer and surgical and functional anatomy. His work explores the intricate relationship between microbial DNA and cancer progression, particularly the role of Fusobacterium nucleatum in colorectal cancer patients. He is actively investigating the gut microbiome’s composition and its implications for treatment outcomes in stages II and III colorectal cancer. Additionally, his research extends to the anatomical intricacies involved in surgical procedures, aiming to enhance surgical outcomes through improved understanding of anatomy. Dr. Tsiaoussis’s interdisciplinary approach combines molecular biology, clinical research, and surgical education, contributing valuable insights to the medical community. His publications reflect a commitment to advancing knowledge that directly impacts clinical practice and patient care. Through his ongoing research efforts, Dr. Tsiaoussis strives to bridge the gap between basic science and clinical applications, making significant contributions to the field of translational oncology.

Publication Top Notes:

  1. Circulating Bacterial DNA in Colorectal Cancer Patients: The Potential Role of Fusobacterium nucleatum 📄
  2. Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy 🌐
  3. Exploring Gut Microbiome Composition and Circulating Microbial DNA Fragments in Patients with Stage II/III Colorectal Cancer: A Comprehensive Analysis 🔍
  4. Evaluation of a Quality Improvement Intervention to Reduce Anastomotic Leak Following Right Colectomy (EAGLE) 📊
  5. Spinal Accessory Nerve Anatomy in the Posterior Cervical Triangle: A Systematic Review with Meta-Analysis 📚
  6. Online Tours for a Museum of Medicine 🌍
  7. Unraveling the Role of Molecular Profiling in Predicting Treatment Response in Stage III Colorectal Cancer Patients: Insights from the IDEA International Study 📈
  8. Ultrasound Morphometry of the Cervical Vagus Nerve for Daily Clinical Practice: Reference Values for Cross Sectional Area and Fascicle Count 📏
  9. Role of Telomere Length in Human Carcinogenesis (Review) 🧬
  10. Achieving a Textbook Outcome in Colon Cancer Surgery Is Associated with Improved Long-Term Survival 📅

Conclusion:

Dr. John C. Tsiaoussis demonstrates exceptional qualifications for the Research for Best Researcher Award through his prolific publication record, impactful research, and leadership within the academic community. His contributions to the fields of anatomy and cancer research are significant, and he shows potential for further growth in interdisciplinary collaboration and public engagement. Recognizing his efforts with this award would not only honor his achievements but also inspire further innovation in medical research.